IL165255A0 - A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease - Google Patents

A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease

Info

Publication number
IL165255A0
IL165255A0 IL16525503A IL16525503A IL165255A0 IL 165255 A0 IL165255 A0 IL 165255A0 IL 16525503 A IL16525503 A IL 16525503A IL 16525503 A IL16525503 A IL 16525503A IL 165255 A0 IL165255 A0 IL 165255A0
Authority
IL
Israel
Prior art keywords
nmda
antagonist
teh
alzheimer
disease
Prior art date
Application number
IL16525503A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL165255(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL165255A0 publication Critical patent/IL165255A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
IL16525503A 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease IL165255A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
IL165255A0 true IL165255A0 (en) 2005-12-18

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16525503A IL165255A0 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease

Country Status (17)

Country Link
EP (1) EP1509232B1 (xx)
JP (1) JP2005528431A (xx)
AT (1) ATE414519T1 (xx)
AU (1) AU2003227516B2 (xx)
BR (1) BR0311375A (xx)
CY (1) CY1108725T1 (xx)
DE (1) DE60324788D1 (xx)
DK (1) DK1509232T3 (xx)
ES (1) ES2314200T3 (xx)
IL (1) IL165255A0 (xx)
MX (1) MXPA04011762A (xx)
NO (1) NO332754B1 (xx)
NZ (1) NZ536603A (xx)
PL (1) PL373903A1 (xx)
PT (1) PT1509232E (xx)
SI (1) SI1509232T1 (xx)
WO (1) WO2003101458A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006900A (es) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
US20060020042A1 (en) * 2004-01-05 2006-01-26 Forest Laboratories, Inc. Memantine for the treatment of mild and mild to moderate Alzheimer's disease
EP1708707A1 (en) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
WO2005092009A2 (en) * 2004-03-19 2005-10-06 Axonyx, Inc. Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
EP1827385B1 (en) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EP1878444B1 (en) * 2005-04-28 2015-09-09 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011276036B2 (en) 2010-07-05 2014-05-22 Gambro Lundia Ab An ambulatory ultrafiltration device, related methods and a computer program product
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
AP2015008498A0 (en) * 2012-12-13 2015-05-31 Lundbeck & Co As H Compositions comprising vortioxetine and donepezil
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MA45002B1 (fr) * 2016-05-18 2020-10-28 Suven Life Sciences Ltd Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
PT3843702T (pt) 2019-05-31 2023-10-13 Tecnimede Soc Tecnico Medicinal Lda Combinação de dose fixa de libertação imediata de memantina e donepezilo

Also Published As

Publication number Publication date
NO20045434L (no) 2004-12-13
DE60324788D1 (de) 2009-01-02
CY1108725T1 (el) 2014-04-09
EP1509232B1 (en) 2008-11-19
SI1509232T1 (sl) 2009-04-30
NZ536603A (en) 2007-06-29
DK1509232T3 (da) 2009-02-23
WO2003101458A1 (en) 2003-12-11
MXPA04011762A (es) 2005-03-31
ATE414519T1 (de) 2008-12-15
AU2003227516A1 (en) 2003-12-19
BR0311375A (pt) 2005-03-15
ES2314200T3 (es) 2009-03-16
PL373903A1 (en) 2005-09-19
JP2005528431A (ja) 2005-09-22
NO332754B1 (no) 2013-01-07
AU2003227516B2 (en) 2008-03-20
EP1509232A1 (en) 2005-03-02
PT1509232E (pt) 2009-01-07

Similar Documents

Publication Publication Date Title
IL165255A0 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
GB0223040D0 (en) Therapeutic compounds
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
GB0005251D0 (en) Therapeutic compounds
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
NO996578L (no) Urokinase-inhibitorer
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
AU7031500A (en) Therapeutic quinazoline compounds
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
ATE234282T1 (de) Polymorphe verbindungen
TR200101120T2 (tr) Serin proteaz inhibitörü
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis
GB9907571D0 (en) Compounds
RS20050420A (xx) Prevencija i lečenje alzheimer-ove bolesti
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
SE0004827D0 (sv) Therapeutic compounds
EP0976404A3 (en) A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
PT1276722E (pt) Inibidores de naftamidina-uroquinase
RS20050514A (xx) Jedinjenja koja inhibiraju prolil oligopeptidazu